AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02523157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellbeing Plan
Description: The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.
Study NCT02523157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control task
Description: Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
Study NCT03629340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks
Study NCT03629340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
Study NCT02613468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collection of periodontal records
Description: 1. Clinic attachment level~2. Probing depth~3. Gingival index~4. Plaque index~5. Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester.
Study NCT02613468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: collection of periodontal records
Description: 1. Clinic attachment level~2. Probing depth~3. Gingival index~4. Plaque index~5. Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester.
Study NCT02613468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pregnancy parameters
Description: Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
Study NCT02613468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pregnancy parameters
Description: Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
Study NCT03155100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib for Inj 60 milligram (MG)
Description: All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
Study NCT03155100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab 400 MG
Description: All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
Study NCT02613468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial Periodontal Therapy
Description: Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
Study NCT02876107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT00252694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan
Description: 32 mg oral tablet
Study NCT03156543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Dressing
Description: This is a standard of care bandage that will be placed on participants in group A post operatively
Study NCT01995240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: 0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
Study NCT01499368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lafutidine
Description: Lafutidine 20mg/day
Study NCT01499368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Famotidine 40mg/day
Study NCT01499368 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: Omeprazole 20mg/day
Study NCT04742452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Capusular Reconstruction
Description: Superior capsular reconstruction is one treatment option for massive and irreparable rotator cuff tears. The superior shoulder capsule, a thin membranous structure located on the inferior surface of the supraspinatus and infraspinatus muscles, is often torn in this type of rotator cuff tear. In superior capsular reconstruction, this structure is reconstructed with acellular dermal allograft.
Study NCT04742452 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Partial Rotator Cuff Repair
Description: Partial rotator cuff repair can be performed, in conjunction with other procedures such as subacromial decompression and biceps tenodesis, when a rotator cuff tear is not amenable to a complete repair.
Study NCT04268199 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib Injection
Description: Subcutaneous injection
Study NCT02710565 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cohort
Description: Obtaining additional EBUS TBNA samples for cell culture
Study NCT02206568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URAL
Study NCT01166113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide, Cyclophosphamide, Prednisone
Description: Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d
Study NCT05872646 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical assessment
Description: clinical staging
Study NCT05872646 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: clinical assessment
Description: clinical staging
Study NCT03495310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness is a method based on the concentration of attention, awareness and meditation, which has been used successfully to reduce stress, depression and anxiety in individuals with some pathology in the short term
Study NCT01760538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: exercise training
Study NCT01760538 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: received usual medical care after heart transplantation
Study NCT03325296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 124249
Description: Ointment containing LEO 124249
Study NCT03325296 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ointment vehicle
Description: Ointment without active ingredients
Study NCT02244840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic bidet
Description: commercial electronic bidet
Study NCT02244840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sitz bath
Description: Conventional sitz bath
Study NCT01377610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naltrexone
Description: Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.
Study NCT01377610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Following detoxification with buprenorphine \[8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)\] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.
Study NCT01377610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivitrol
Description: dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
Study NCT02043912 — intervention group
Intervention type: DRUG
Intervention: Haloperidol
Study NCT04117490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epiitalis
Description: Two capsules twice daily 30 mins before meals (breakfast \& dinner).
Study NCT04117490 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules twice daily 30 mins before meals (breakfast \& dinner).
Study NCT03321864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound scan of prostate
Description: Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
Study NCT04403152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-operative rehabilitation
Description: Patients received the exercises programme for five days, 30 minutes, two times per day with supervision by a physical therapist.
Study NCT04403152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative mobilization
Description: Patients received usual mobilization programme for 2-5 minutes, two times per day the five days with supervision by a physical therapist.
Study NCT02928302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TVU CL screening
Description: Transvaginal ultrasound cervical length screening
Study NCT03556592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
Study NCT03556592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 1x 100 mg tablet
Study NCT03556592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 2x 5 mg tablets
Study NCT03556592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 1x 20 mg capsule
Study NCT03556592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: 1x 100 mg tablet
Study NCT03556592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: 1 mL of 2 mg/mL oral solution/syrup
Study NCT02050347 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19.CAR-CD28Z T Cells - dose escalation 2
Description: Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10\^5 cells/kg~Dose Level 2: 1×10\^6 cells/kg~Dose Level 3: 5×10\^6 cells/kg
Study NCT02050347 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19.CAR-CD28Z T Cells - dose escalation 1
Description: Patients will receive one of the following doses:~Dose Level one: 1x10\^5 cells/kg~Dose Level 2: 5x10\^5 cells/kg~Dose Level 3: 1x10\^6 cells/kg
Study NCT02689466 — intervention group
Intervention type: DRUG
Intervention: [18F]FP-TZTP
Description: radioligand
Study NCT04414592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.
Study NCT03554941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noise stimulation
Description: noise stimulation
Study NCT02091531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Study NCT00945529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide (iNO)
Description: Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
Study NCT04023591 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery/Occupational Therapy
Description: Surgery based on function and injury/ Occupational therapy for 48 months post-surgery
Study NCT01080521 — intervention group
Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Ancillary studies
Study NCT03926533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Telehealth visits will be conducted from a private telehealth lab room in the Vanderbilt ICU Recovery Center using a live and interactive approach where providers and patients interact and communicate in real-time using Zoom, a secure video-conferencing platform recommended by Vanderbilt Telehealth.
Study NCT00726037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontak
Description: One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
Study NCT02392390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical Dynamic Phototherapy (TDP)
Description: Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
Study NCT02392390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvixia cream
Study NCT03401944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPN
Study NCT03401944 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT01080521 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06397014 — intervention group
Intervention type: PROCEDURE
Intervention: D-type stoma lateral hernia repair
Description: underwent D-type stoma lateral hernia repair
Study NCT02406976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G1 -Exercise
Description: 20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.~Furthermore the similar treatment to G3.
Study NCT02406976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G2- Exercise and Lifestyle
Description: Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.~Furthermore the similar treatment to G3.
Study NCT02406976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G3- Control
Description: Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
Study NCT02406976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: G3- Control
Description: Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
Study NCT04567706 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples
Study NCT02668900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support
Description: The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
Study NCT02200003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attention bias modification for anxiety
Study NCT02200003 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: attention bias modification for anxiety
Study NCT00562263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Dietary modification and regular physical activity
Study NCT03155100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
Study NCT02266654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV fluids
Description: Normal Saline 0.9%
Study NCT04267848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04267848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04267848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT04267848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04267848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT02896491 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Exposure with non-ionizing electromagnetic fields
Description: In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
Study NCT02896491 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Exposure with non-ionizing electromagnetic fields
Description: In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
Study NCT00522418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal Nerve Simulation (VNS) Therapy
Description: VNS Therapy + Best Medical Practice including anti-epileptic drugs
Study NCT00522418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Practive
Description: Best Medical Practice including anti-Epileptic Drugs
Study NCT03537365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum (BC) / intervention group
Description: Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l.~The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM.~The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an early discharge program), or are transferred to non-participating neonatal units, whichever comes first.
Study NCT03537365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FM85 / control group
Description: Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l.~The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM.~FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed.
Study NCT00653848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel 75 mg/square meter i.v. every third week, six cycles
Study NCT02954406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 immediate release tablet
Study NCT04267848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04441021 — intervention group
Intervention type: OTHER
Intervention: Penicillin Allergy Risk Stratification and Evaluation
Description: This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
Study NCT03825315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAXI 80 U
Description: DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)